Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study Academic Article uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Certolizumab Pegol
  • Methotrexate

abstract

  • NCT01519791.

publication date

  • May 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5264210

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2015-209057

PubMed ID

  • 27165179

Additional Document Info